- Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US
- Immatics to receive upfront payment of $150 million and additional milestone payments of up to $770 million plus tiered double-digit royalties on net product sales
Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE: BMY), today announced that they have entered into a license, development and commercialization agreement (the “agreement”) for Immatics’ TCR Bispecific candidate, IMA401.